Sonnet BioTherapeutics Holdings, Inc.
SONN · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | – | $4 | $3 | $6 |
| - Cash | $5 | $0 | $2 | $3 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $4 | $1 | $4 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 5,268.8% | -87.4% | -57.8% | – |
| Gross Profit | $0 | $0 | $0 | -$21 |
| % Margin | 0% | 100% | 100% | -6,027.9% |
| EBITDA | -$16 | -$12 | -$19 | -$30 |
| % Margin | -1,584.4% | -63,171.7% | -12,663.2% | -8,451.7% |
| Net Income | -$16 | -$7 | -$19 | -$30 |
| % Margin | -1,611.3% | -39,929.3% | -12,741.6% | -8,508.3% |
| EPS Diluted | -3.95 | -11.35 | -145.12 | -1,203.05 |
| % Growth | 65.2% | 92.2% | 87.9% | – |
| Operating Cash Flow | -$13 | -$9 | -$21 | -$28 |
| Capital Expenditures | $0 | $0 | -$0 | -$1 |
| Free Cash Flow | -$13 | -$9 | -$22 | -$29 |